Neu H C, Bennett J E, Bodey G P, Rubin R H, Schentag J J, Sugar A M
College of Physicians and Surgeons of Columbia University, New York City.
Hosp Formul. 1990 Mar;25 Suppl B:9-14.
Fluconazole is a new antifungal agent available in both oral and parenteral formulations. According to the experts in this roundtable discussion, fluconazole represents a major clinical advance in the treatment of candidiasis and cryptococcosis in cancer patients, patients with AIDS, organ transplant recipients, and other patients at risk for opportunistic mycoses. The pharmacokinetic profile for fluconazole permits infrequent dosing and also makes it ideal for tissue site infections. Fluconazole's low toxicity gives it an advantage over currently available antifungal therapy and will permit prompt presumptive treatment of selected infections.
氟康唑是一种新型抗真菌药，有口服和注射两种剂型。据本次圆桌讨论的专家称，氟康唑在治疗癌症患者、艾滋病患者、器官移植受者以及其他有机会性霉菌感染风险的患者的念珠菌病和隐球菌病方面代表了一项重大的临床进展。氟康唑的药代动力学特征允许给药频率低，也使其成为组织部位感染的理想药物。氟康唑的低毒性使其优于目前可用的抗真菌治疗方法，并将允许对选定的感染进行及时的经验性治疗。
